The supplemental biological license application (sBLA) was submitted by Bristol-Myers Squibb Company to meet expected long-term demand for Orencia.
Jung-Jin Seo, chairman and CEO of Celltrion, said: “Achieving sBLA approval from the FDA to manufacture Orencia is an important milestone that reinforces our vision to become a fully integrated global biotechnology company.”